What is Wet Macular Degeneration? Symptoms, Causes, and Treatment Options

What is Wet Macular Degeneration? Symptoms, Causes, and Treatment Options

October 29, 2026

Key Takeaways

  • Wet macular degeneration (also called neovascular AMD) is the less common form of age-related macular degeneration (AMD), making up about 10% of cases, but it’s behind roughly 90% of the severe vision loss the disease causes.
  • Watch for wavy or bent straight lines and a blurry or dark smudge in your central vision. These changes can show up within a day, and prompt evaluation and treatment are important because untreated wet AMD can lead to permanent central vision loss.
  • The standard treatment is a series of eye injections called anti-VEGF therapy. Some newer options may allow longer intervals up to every 4 to 5 months, once your eyes are responding well.
  • Being 55 or older, smoking, cardiovascular disease, and certain genes (like CFH and ARMS2) are the biggest known risk factors, though wet AMD can develop in anyone.
  • Vision that’s already lost from wet AMD usually can’t be fully restored, but many people who stay on treatment are able to stabilize their sight, and some regain part of what they lost.

You’re scrolling away on your phone, or reading the mail, and something looks off. The lines on the page seem wavy, almost underwater, or maybe there’s a smudgy gray patch sitting right where you’re trying to look.

Your first reaction probably wasn’t curiosity, it was worry. That’s reasonable, and a good instinct to act on, because what you’re describing could be wet macular degeneration, also called neovascular age-related macular degeneration (AMD).

Here’s what’s actually happening inside your eye when you have wet AMD: tiny, fragile blood vessels start growing where they shouldn’t, underneath the macula, the part of your retina responsible for the sharp, detailed vision you use to read, drive, and recognize faces. Those vessels leak fluid or blood, and that leakage is what distorts what you see. It can happen fast, sometimes your vision shifts within a single day, which is why catching it early matters so much.

The standard treatment today is a series of in-office eye injections called anti-VEGF therapy to slow or stabilize vision loss. If this is your journey, well-coordinated care can make a huge difference in how you manage daily tasks and maintain your independence.

What Is Wet Macular Degeneration?

Think of wet macular degeneration as the more aggressive of the two types of AMD. It develops when abnormal blood vessels form underneath the retina and push toward the macula, a process providers call choroidal neovascularization (new blood vessels growing where they don’t belong). Those vessels are fragile, so they leak fluid or blood, distorting or damaging the sharp central vision your macula provides.

The “dry” form of AMD, by contrast, usually progresses slowly over years as the macula thins. Wet AMD, on the other hand, can cause sudden vision changes, sometimes within a single day, with permanent damage setting in within weeks to months if untreated.

The macula covers only a small part of your retina, but it does most of the work for reading, faces, and fine detail, so damage there is felt immediately, which is why wet AMD, despite making up only about 10% of AMD cases, is responsible for around 90% of the legal blindness linked to the disease.

Risk Factors and Heredity

Age is the single biggest risk factor. Your odds of developing AMD go up substantially once you pass 55, and it’s most common after 60.

Smoking roughly doubles your risk compared with people who’ve never smoked, one of the few risk factors you actually control.

Cardiovascular disease and high blood pressure are also linked to a higher risk, and carrying extra weight may raise the odds of progressing to more severe disease.

Can you inherit it? To a real degree, yes. Gene variants like CFH and ARMS2 are tied to higher AMD risk, and researchers have connected nearly 20 genes overall to the condition. A parent or sibling with AMD raises your own odds, though family history alone doesn’t guarantee you’ll develop it, and it’s diagnosed more often in white populations than Black or Hispanic populations, though anyone can develop it. If this puts you in a higher-risk group, ask your provider about more frequent exams.

Symptoms and How It Impacts Your Vision

Wet AMD tends to announce itself faster and feel more disruptive than the dry form. Symptoms can develop suddenly and may worsen over a short period of time.

Common signs include:

  • Straight lines appearing wavy or bent (called metamorphopsia)
  • A blurry, dark, or empty spot in the center of your vision
  • A sudden decrease in sharp, central vision
  • Colors appearing less vivid than usual

Here’s some good news in the middle of this: your peripheral (side) vision typically stays intact, so wet AMD on its own doesn’t cause total blindness. However, losing central vision can make everyday activities much more difficult, including reading, driving, cooking, and recognizing faces.

If you notice new distortion, blurriness, or other changes in your vision, don’t wait to get them checked. Many eye care providers recommend using an Amsler grid at home (a simple grid with a center dot) to help monitor for changes between appointments.

How Providers Diagnose Wet Macular Degeneration

If your provider suspects wet macular degeneration, the workup usually starts with a dilated eye exam, then imaging.

One key tool is optical coherence tomography (OCT), a painless scan that creates detailed cross-section images of your retina, showing fluid buildup beneath or within the macula.

Another common test is fluorescein angiography, where dye is injected into a vein in your arm, then photographs it moving through your eye’s blood vessels to reveal leakage. A newer, dye-free option, optical coherence tomography angiography (OCTA), maps that same blood flow.

Together, these tools show your provider exactly where the abnormal vessels are and which treatment fits you.

Treatment Options

Here’s the encouraging part: wet AMD is treatable, and many people who start treatment promptly see their vision stabilize, sometimes it even improves. The goal is always the same: stop the leaking vessels before they cause more damage. There are three approaches: anti-VEGF injections, photodynamic therapy, and laser therapy, and for most people today, injections are where treatment starts and stays.

Anti-VEGF Injection Therapy

It helps to know what’s driving the problem first. Your body makes a protein called vascular endothelial growth factor, or VEGF, that signals blood vessels to grow. In wet AMD, there’s too much of it, triggering those abnormal vessels under your retina. Anti-VEGF medications block that signal. A retina specialist injects the medication directly into your eye (it sounds worse than it is, most people describe pressure, not pain), reducing leakage and, over time, possibly shrinking the vessels.

Several FDA-approved options exist, differing mainly in dosing frequency:

Medication Generic Name Typical Dosing (After Loading) Extended Dosing Key Consideration
Eylea HD aflibercept 8 mg every 8-16 weeks Up to every 20 weeks after 1 year Widest approved dosing range
Vabysmo faricimab Individualized, optional regimens of every 8 weeks, every 12 weeks, and every 16 weeks Targets two growth-factor pathways
Eylea aflibercept 2 mg every 8 weeks Up to every 12 weeks after 1 year Long real-world track record
Lucentis ranibizumab 0.5mg once a month (about every 28 days) Every 3 months after 3 or 4 consecutive monthly doses Longest-running trial data
Beovu brolucizumab 6mg every 8-12 weeks FDA warning for retinal vasculitis and vascular occlusion

Avastin is another option, however it is not FDA-approved for wet AMD.

Avastin bevacizumab Individualized; no FDA-approved eye dosing schedule Used off-label; substantially lower cost

Vision outcomes tend to be broadly similar across these options when you stay on schedule, so the real differences come down to appointment frequency and cost.

Eylea HD and Vabysmo have become some of the most widely prescribed newer options, largely because they allow longer stretches between visits. Cost is worth thinking about too, specialty injectable medications like these carry a significantly high price tag, which is exactly what Acelpa Health’s affiliated pharmacies can help you sort through.

Photodynamic Therapy

Photodynamic therapy (PDT) works differently: a light-activated drug called verteporfin is infused into a vein, then a low-energy (“cold”) laser activates it, and the activated drug damages the walls of those leaking vessels while sparing the healthy retina around it. It isn’t usually first-line anymore, but it’s still useful for a subtype called polypoidal choroidal vasculopathy (PCV), sometimes paired with anti-VEGF injections.

Laser Therapy

Thermal laser photocoagulation is the older approach, used far less often today, aiming a focused beam of light directly at leaking vessels to seal them. The tradeoff: it creates a small permanent blind spot in the treated tissue, so providers reserve it for vessels safely away from the macula’s center.

Can Vision Loss Improve?

This is probably the question on your mind more than any other, and the honest answer is: sometimes, yes.

Anti-VEGF therapy hasn’t just helped people hold steady, it’s helped many regain vision they’d already lost. In the pivotal Lucentis (ranibizumab) trials, about 31% to 37% of people gained at least 15 letters on a standard eye chart at 12 months, versus just 6% to 11% of those untreated. Eylea (aflibercept) showed similar results, with roughly 31% gaining at least 15 letters, while Vabysmo (faricimab) trials measured an average gain of about 6 letters, comparable to Eylea.

Can vision loss be reversed completely? In most cases, no; damage that’s already happened to the macula doesn’t fully repair itself. How much you recover depends on how much damage occurred first, where the vessels are, and how your eyes respond.

But stopping further progression, and regaining some functional vision, is realistic for a lot of people who stay engaged with their treatment.

How to Care for Your Vision

While there’s no way to prevent wet AMD completely, there are steps you can take to help protect your vision and support your overall eye health.

Here are a few habits that can make a difference:

  • Quit smoking if you smoke. Smoking is one of the strongest risk factors for AMD, and quitting can help at any stage.
  • Manage your heart health. Keeping your blood pressure and cholesterol under control supports the health of the tiny blood vessels in your eyes.
  • Ask about AREDS2 supplements. The AREDS2 formula (a combination of vitamins C and E, lutein, zeaxanthin, and zinc) has been shown in NIH-funded research to reduce the risk of progressing to advanced AMD by about 25% in people who meet the criteria.
  • Protect your eyes from UV exposure. While the link between UV light and AMD isn’t fully established, many eye care providers still recommend wearing UV-blocking sunglasses as part of good eye health.
  • Use an Amsler grid at home. This simple tool can help you spot changes in your central vision between appointments so you can report them promptly.

These steps can’t replace treatment, but they can help you take an active role in protecting your vision and catching changes early.

Adapting to Vision Changes

Living with wet macular degeneration usually means adjusting to a new normal, even once treatment is working. What helps most depends on which everyday tasks feel hardest for you:

  • Magnification tools and large-print materials for reading
  • High-contrast settings on your phone or computer
  • Brighter, more targeted lighting where you read, cook, or do close work
  • Learning to use your peripheral vision more deliberately for certain tasks

A low-vision specialist can walk you through which devices or strategies would help most with what you’re finding difficult. You don’t have to figure this out alone.

When to Contact Your Eye Care Provider

Any sudden change in your central vision deserves a same-day or next-day call to your provider, not a wait-and-see approach. That includes new waviness in straight lines, a blurry or dark spot, or vision that suddenly feels less sharp. Wet AMD can worsen quickly, and the window for preserving your vision is often narrower than people expect.

If you’re already being treated, showing up to every scheduled appointment matters as much as the medication itself, and finding a location that fits your routine can make that easier to stick with.

Skipping visits lets abnormal vessels become active again, and that damage can be harder to undo. If you notice new distortion between appointments, don’t wait, call your retina specialist right away.

Moving Forward With Wet AMD Care

Wet macular degeneration is serious, but it’s also a condition where acting quickly genuinely changes what happens next.

Anti-VEGF injection therapy has transformed what’s possible, and newer options like Eylea HD (aflibercept 8 mg) and Vabysmo (faricimab) have made treatment more manageable by stretching out time between appointments. The biggest factor in your outcome is consistency: showing up, watching for changes, and leaning on support that keeps your care on track.

If you or someone you love is navigating this diagnosis, the team at Acelpa Health’s affiliated pharmacies is ready to help coordinate medication access and keep your treatment schedule moving. Reach out to Acelpa Health’s affiliated pharmacies for support through your specialty eye care journey.

Frequently Asked Questions (FAQ):

How serious is wet macular degeneration?

It’s a serious eye condition that can cause rapid vision loss if untreated. Abnormal vessels grow under the retina and leak fluid or blood, damaging the macula, the part of the eye responsible for sharp central vision. Permanent damage can set in within weeks to months. The good news: with today’s treatments, many people stabilize their vision, and some regain part of the vision they’ve lost.

What is the best treatment for wet macular degeneration right now?

For most people, anti-VEGF eye injections are the standard of care. They block a protein that fuels abnormal blood vessel growth and are given directly into the eye by a retina specialist. Some newer options allow injections as infrequently as every few months once your eyes respond well. Laser and photodynamic therapy are still used in specific situations, but aren’t first-line anymore.

What should you avoid if you have wet macular degeneration?

Smoking is one of the biggest things to avoid, it raises your risk and speeds up progression. Staying on top of blood pressure and cholesterol matters too, as does never skipping scheduled appointments: missing injections lets abnormal vessels become active again, sometimes causing harder-to-reverse damage.

What’s the difference between wet and dry macular degeneration?

Dry macular degeneration is more common and develops slowly over years as the macula thins. Wet macular degeneration is less common but far more aggressive: abnormal vessels grow under the retina and leak fluid or blood, causing changes within days to weeks. Dry AMD can also progress into wet AMD, part of why regular eye exams matter even when your vision feels fine.

How often will I need anti-VEGF eye injections?

It depends on the medication and how your eyes respond. Most plans start with monthly injections to bring abnormal vessels under control, then space out from there. Some newer medications allow appointments as infrequently as every few months for people who respond well, while others need more frequent dosing. Sticking to your schedule, even once symptoms improve, is one of the most important things you can do for your vision long term.

References:

  1. American Academy of Ophthalmology (AAO), 2026a. Straight Lines Look Bent or Wavy? [online] Available at: https://www.aao.org/eye-health/symptoms/straight-lines-look-bent-wavy [Accessed 20 July 2026].
  2. American Academy of Ophthalmology (AAO), 2026b. Six Things You Should Know About AMD. [online] Available at: https://www.aao.org/eye-health/tips-prevention/six-things-about-amd [Accessed 20 July 2026].
  3. American Academy of Ophthalmology (AAO), 2026c. What Is Optical Coherence Tomography? [online] Available at: https://www.aao.org/eye-health/treatments/what-is-optical-coherence-tomography [Accessed 20 July 2026].
  4. American Academy of Ophthalmology (AAO), 2026d. Can Sunglasses Help Prevent Macular Degeneration? [online] Available at: https://www.aao.org/eye-health/tips-prevention/sunglasses-glasses-amd-macular-degeneration [Accessed 20 July 2026].
  5. American Academy of Ophthalmology (AAO) EyeWiki, 2026a. Age-Related Macular Degeneration. [online] Available at: https://eyewiki.aao.org/Age-Related_Macular_Degeneration [Accessed 20 July 2026].
  6. American Academy of Ophthalmology (AAO) EyeWiki, 2026b. Optical Coherence Tomography Angiography. [online] Available at: https://eyewiki.aao.org/Optical_Coherence_Tomography_Angiography [Accessed 20 July 2026].
  7. BrightFocus Foundation, 2026a. Macular Degeneration: Facts & Figures. [online] Available at: https://www.brightfocus.org/macular/facts-figures/ [Accessed 20 July 2026].
  8. BrightFocus Foundation, 2026b. Symptoms of Wet Age-Related Macular Degeneration. [online] Available at: https://www.brightfocus.org/resource/symptoms-of-wet-age-related-macular-degeneration/ [Accessed 20 July 2026].
  9. Centers for Disease Control and Prevention (CDC), 2026. Age-Related Macular Degeneration (AMD) Prevalence Estimates. [online] Available at: https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html [Accessed 20 July 2026].
  10. Centers for Disease Control and Prevention (CDC), 2011. Smoking Cessation and the Risk of Tobacco-Related Eye Disease. Preventing Chronic Disease. [online] Available at: https://www.cdc.gov/pcd/issues/2011/nov/10_0179.htm [Accessed 20 July 2026].
  11. Cleveland Clinic, 2026a. Wet Macular Degeneration. [online] Available at: https://my.clevelandclinic.org/health/diseases/wet-macular-degeneration [Accessed 20 July 2026].
  12. Cleveland Clinic, 2026b. Amsler Grid Eye Test. [online] Available at: https://my.clevelandclinic.org/health/diagnostics/amsler-grid-eye-test [Accessed 20 July 2026].
  13. Food and Drug Administration (FDA), 2026. Eylea HD (Aflibercept Injection) Prescribing Information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761355s005lbl.pdf [Accessed 20 July 2026].
  14. Food and Drug Administration (FDA), 2024a. Eylea (Aflibercept Injection) Prescribing Information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125387s087lbl.pdf [Accessed 20 July 2026].
  15. Food and Drug Administration (FDA), 2024b. Vabysmo (Faricimab-svoa Injection) Prescribing Information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761235s005lbl.pdf [Accessed 20 July 2026].
  16. Food and Drug Administration (FDA), 2024c. Lucentis (Ranibizumab Injection) Prescribing Information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125156s128lbl.pdf [Accessed 20 July 2026].
  17. Food and Drug Administration (FDA), 2022. Beovu (Brolucizumab-dbll Injection) Prescribing Information. [online] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761125s010s012s013lbl.pdf [Accessed 20 July 2026].
  18. Heier, J.S., Khanani, A.M., Quezada Ruiz, C., et al., 2022. Efficacy, Durability, and Safety of Intravitreal Faricimab up to Every 16 Weeks for Neovascular Age-Related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-Masked, Phase 3, Non-Inferiority Trials. The Lancet. [online] Available at: https://pubmed.ncbi.nlm.nih.gov/35085502/ [Accessed 20 July 2026].
  19. Mayo Clinic, 2026a. Wet Macular Degeneration: Symptoms and Causes. [online] Available at: https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/symptoms-causes/syc-20351107 [Accessed 20 July 2026].
  20. Mayo Clinic, 2026b. Wet Macular Degeneration: Diagnosis and Treatment. [online] Available at: https://www.mayoclinic.org/diseases-conditions/wet-macular-degeneration/diagnosis-treatment/drc-20351113 [Accessed 20 July 2026].
  21. Mayo Clinic, 2026c. Dry Macular Degeneration: Symptoms and Causes. [online] Available at: https://www.mayoclinic.org/diseases-conditions/dry-macular-degeneration/symptoms-causes/syc-20350375 [Accessed 20 July 2026].
  22. Mayo Clinic, 2026d. Cataracts: Symptoms and Causes. [online] Available at: https://www.mayoclinic.org/diseases-conditions/cataracts/symptoms-causes/syc-20353790 [Accessed 20 July 2026].
  23. MedlinePlus, 2026a. CFH Gene. [online] Available at: https://medlineplus.gov/genetics/gene/cfh/ [Accessed 20 July 2026].
  24. MedlinePlus, 2026b. Photocoagulation. [online] Available at: https://medlineplus.gov/ency/article/007664.htm [Accessed 20 July 2026].
  25. National Eye Institute (NEI), 2026a. Age-Related Macular Degeneration (AMD). [online] Available at: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration [Accessed 20 July 2026].
  26. National Eye Institute (NEI), 2023. What You Should Know About Age-Related Macular Degeneration. [online] Available at: https://www.nei.nih.gov/sites/default/files/2023-02/WhatYouShouldKnow_AMD.pdf [Accessed 20 July 2026].
  27. National Eye Institute (NEI), 2026b. Treatments for Wet AMD (Advanced Neovascular AMD). [online] Available at: https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/treatments-wet-amd-advanced-neovascular-amd [Accessed 20 July 2026].
  28. National Eye Institute (NEI), 2026c. About AREDS and AREDS2. [online] Available at: https://www.nei.nih.gov/eye-health-information/clinical-trials/age-related-eye-disease-studies-aredsareds2/about-areds-and-areds2 [Accessed 20 July 2026].
  29. National Eye Institute (NEI), 2012. Avastin and Lucentis Are Equivalent in Treating Age-Related Macular Degeneration. [online] Available at: https://www.nei.nih.gov/research-and-training/research-news/avastin-and-lucentis-are-equivalent-treating-age-related-macular-degeneration [Accessed 20 July 2026].

Disclaimer:

The content provided on this blog is for informational purposes only and is not intended to serve as medical advice, diagnosis, or treatment. While we make every effort to provide accurate and up-to-date information, the details shared here should not be considered a substitute for professional medical consultation or advice.

By accessing this blog, you agree to hold harmless the author, publisher, and any associated parties from any claims, liabilities, or damages arising from the use or interpretation of this content.

©2026 Acelpa Health, LLC. All rights reserved.